GeneDx (NASDAQ:WGS) PT Raised to $11.00 at The Goldman Sachs Group

GeneDx (NASDAQ:WGS) had its target price lifted by The Goldman Sachs Group to $11.00 in a report released on Monday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

GeneDx Trading Up 4.0 %

Shares of NASDAQ:WGS opened at $9.57 on Monday. The company has a market cap of $249.30 million, a PE ratio of -1.29 and a beta of 2.75. The company’s 50-day moving average price is $8.47 and its 200 day moving average price is $4.70. GeneDx has a fifty-two week low of $1.16 and a fifty-two week high of $12.24. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.23.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.01. The firm had revenue of $57.42 million for the quarter, compared to the consensus estimate of $57.00 million. GeneDx had a negative net margin of 86.77% and a negative return on equity of 49.64%. Sell-side analysts anticipate that GeneDx will post -2.02 earnings per share for the current year.

Insider Activity at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,253 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $10.59, for a total transaction of $34,449.27. Following the sale, the chief financial officer now directly owns 28,927 shares in the company, valued at approximately $306,336.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other GeneDx news, CEO Katherine Stueland sold 8,559 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $10.59, for a total transaction of $90,639.81. Following the sale, the chief executive officer now directly owns 66,698 shares in the company, valued at approximately $706,331.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Feeley sold 3,253 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $10.59, for a total transaction of $34,449.27. Following the sale, the chief financial officer now owns 28,927 shares in the company, valued at $306,336.93. The disclosure for this sale can be found here. Insiders have sold a total of 14,013 shares of company stock worth $146,979 in the last ninety days. 28.10% of the stock is owned by insiders.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently made changes to their positions in WGS. BlackRock Inc. bought a new stake in shares of GeneDx in the 1st quarter worth approximately $8,220,000. CVI Holdings LLC purchased a new position in shares of GeneDx in the first quarter worth approximately $3,562,000. Geode Capital Management LLC purchased a new position in shares of GeneDx in the first quarter worth approximately $3,129,000. HighTower Advisors LLC purchased a new position in shares of GeneDx in the first quarter worth approximately $2,045,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of GeneDx in the first quarter worth approximately $1,335,000. 61.72% of the stock is currently owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.